Latest Posts › Patents

Share:

Sherry Knowles Addresses Real World Impact of Myriad-Mayo Guidance at BIO Symposium

Last month, at the Biotechnology Industry Organization (BIO) IP & Diagnostics Symposium in Alexandria, VA, Sherry Knowles of Knowles IP Strategies addressed the impact of the U.S. Patent and Trademark Office's Myriad-Mayo...more

10/16/2014 - Biotechnology Guidance Update Mayo v. Prometheus Myriad-Mayo Patent-Eligible Subject Matter Patents Pharmaceutical Patents USPTO

Inovia Releases 2014 Report on Global Patent Trends

Patent services provider inovia has released its fifth annual report on global patent and IP trends. In compiling "The 2014 U.S. Global Patent & IP Trends Indicator," inovia, which produces products for PCT national phase...more

9/24/2014 - EU Patent Infringement Patent Litigation Patents Popular USPTO

USPTO to Hold Roundtable on Patent Law Harmonization

In a notice published in the Federal Register last week (79 Fed. Reg. 56070), the U.S. Patent and Trademark Office announced that it would be holding a roundtable to obtain public input on several issues related to the...more

9/23/2014 - International Harmonization Patents Public Comment Rulemaking Process USPTO

USPTO Expected to Issue Revised Myriad-Mayo Guidance in October

During a session at today's biotechnology/chemical/pharmaceutical (BCP) customer partnership meeting, the U.S. Patent and Trademark Office provided an update on the status of the Myriad-Mayo Guidance. ...more

9/18/2014 - AMP v Myriad Mayo v. Prometheus Myriad Myriad-Mayo Patents USPTO

AbbVie Inc. v. Mathilda & Terence Kennedy Institute of Rheumatology Trust (Fed. Cir. 2014)

Last month, in AbbVie Inc. v. Mathilda & Terence Kennedy Institute of Rheumatology Trust, the Federal Circuit affirmed a determination by the District Court for the Southern District of New York that U.S. Patent No....more

9/5/2014 - AbbVie Double Patent Obviousness Patent Litigation Patents Pharmaceutical Pharmaceutical Manufacturers Pharmaceutical Patents

Examination of Myriad-Mayo Guidance Comments -- AUTM, COGR, AAU, and APLU

On March 4, the U.S. Patent and Trademark Office issued a guidance memorandum, entitled "Guidance For Determining Subject Matter Eligibility Of Claims Reciting Or Involving Laws of Nature, Natural Phenomena, & Natural...more

8/22/2014 - AMP v Myriad Mayo v. Prometheus Patent Infringement Patent Litigation Patents SCOTUS USPTO

Examination of Myriad-Mayo Guidance Comments -- International Bioindustry Associations

On March 4, the U.S. Patent and Trademark Office issued a guidance memorandum, entitled "Guidance For Determining Subject Matter Eligibility Of Claims Reciting Or Involving Laws of Nature, Natural Phenomena, & Natural...more

8/12/2014 - Biotechnology Mayo v. Prometheus Myriad Myriad-Mayo Patent Litigation Patent-Eligible Subject Matter Patents Pharmaceutical Pharmaceutical Patents Public Comment Rulemaking Process USPTO

Examination of Myriad-Mayo Guidance Comments -- ACLU

On March 4, the U.S. Patent and Trademark Office issued a guidance memorandum entitled "Guidance For Determining Subject Matter Eligibility Of Claims Reciting Or Involving Laws of Nature, Natural Phenomena, & Natural...more

8/6/2014 - ACLU Biotechnology Chemicals CLS Bank v Alice Corp Mayo v. Prometheus Memorandum of Guidance Myriad Myriad-Mayo Patent-Eligible Subject Matter Patents Pharmaceutical Public Comment Section 101 USPTO

USPTO Seeks Public Input on Application Pendency

Earlier this month, the U.S. Patent and Trademark Office published a notice in the Federal Register (79 Fed. Reg. 38854) requesting comments from the public regarding optimal patent first action and total pendency target...more

7/22/2014 - Patent Applications Patent Reform Patents USPTO

Software Sector Leads Pack in 2Q Venture Funding and Biotech Sector Finishes Second

Last week, the National Venture Capital Association (NVCA), a trade association representing the U.S. venture capital industry, released the results of its MoneyTree Report on venture funding for the second quarter of 2014. ...more

7/21/2014 - Biotechnology Funding Medical Devices Patents Pharmaceutical Pricewaterhousecoopers Software Venture Capital

USPTO Proposes Rules Changes in View of Novartis v. Lee

Last month, the U.S. Patent and Trademark Office published a notice of proposed rulemaking in the Federal Register (79 Fed. Reg. 34681) discussing changes to the rules of practice to implement the Federal Circuit's decision...more

7/17/2014 - Novartis Patent Examinations Patents Public Comment Rulemaking Process USPTO

AbbVie Deutschland GmbH v. Janssen Biotech, Inc. (Fed. Cir. 2014) - Absent Description of Representative Species to Support Entire...

Last week, in AbbVie Deutschland GmbH v. Janssen Biotech, Inc., the Federal Circuit affirmed judgments by the District Court for the District of Massachusetts in infringement and interference actions involving AbbVie...more

7/11/2014 - Biotechnology Patent Infringement Patent Litigation Patents

USPTO Holds Forum on Subject Matter Eligibility -- Part IV

On May 9, the U.S. Patent and Trademark Office held a four-hour long forum to receive public feedback on the Myriad-Mayo Guidance, which was issued by the Office on March 4. According to the Office's Guidance webpage, the...more

7/10/2014 - AMP v Myriad Mayo v. Prometheus Patent-Eligible Subject Matter Patents SCOTUS USPTO

IPO Releases List of Top 300 Patent Holders for 2013 - IPO Releases List of Top 300 Patent Holders for 2013

Last month, the Intellectual Property Owners Association (IPO) announced the release of its 31st annual list of the top 300 organizations receiving U.S. patents. Patent Docs Readers may recall that the U.S. Patent and...more

7/8/2014 - Intellectual Property Owners Association Patents Utility Patents

Docs @ BIO: USPTO Provides Update on Myriad-Mayo Guidance

At last week's BIO International Convention in San Diego, Andrew Hirshfeld, USPTO Deputy Commissioner for Patent Examination Policy, and June Cohan, a Legal Advisor with the USPTO's Office of Patent Legal Administration, took...more

7/2/2014 - DNA Genetic Materials Guidance Update Memorandum of Guidance Myriad Myriad-Mayo Patent-Eligible Subject Matter Patents Public Comment Section 101 Stem cells USPTO

USPTO Extends Deadline for Providing Feedback on Myriad-Mayo Guidance

As we reported earlier this week, the period for submitting written comments to the U.S. Patent and Trademark Office regarding the Office's Myriad-Mayo guidance memorandum has been extended to July 31, 2014. The Office...more

6/30/2014 - Memorandum of Guidance Myriad Myriad-Mayo Patent Trial and Appeal Board Patent-Eligible Subject Matter Patents USPTO

Consumer Watchdog v. Wisconsin Alumni Research Foundation (Fed. Cir. 2014) - Appellant's Opposition to Board Decision Not Enough...

Yesterday, the Federal Circuit dismissed an appeal by Consumer Watchdog from a decision of the Patent Trial and Appeal Board affirming the patentability of claims 1-4 of U.S. Patent No. 7,029,913. In dismissing the appeal,...more

6/6/2014 - Article III Patent Infringement Patent Litigation Patents Standing

Limelight Networks, Inc. v. Akamai Technologies, Inc. (2014)

Today, in Limelight Networks, Inc. v. Akamai Technologies, Inc., the Supreme Court determined that a defendant is not liable for inducing infringement of a patent under 35 U. S. C. § 271(b) when no one has directly infringed...more

6/3/2014 - Akamai Technologies Induced Infringement Limelight Limelight Networks Patent Infringement Patent Litigation Patents SCOTUS

USPTO Issues Final Rule to Implement PTA Provisions of AIA Technical Corrections Act and Provide Optional Procedure for Requesting...

On May 15, the U.S. Patent and Trademark Office published a Federal Register notice (79 Fed. Reg. 27755) to adopt as final changes to the rules of practice implementing the patent term adjustment (PTA) provisions of section...more

5/30/2014 - America Invents Act Patent Reform Patent Term Adjustment Patent Terms Patent Trial and Appeal Board Patents USPTO

USPTO Holds Forum on Subject Matter Eligibility -- Part III

Last Friday, the U.S. Patent and Trademark Office held a four-hour long forum to receive public feedback on the Myriad-Mayo Guidance, which was issued by the Office on March 4. According to the Office's Guidance webpage, the...more

5/16/2014 - AMP v Myriad Mayo v. Prometheus Patent Applications Patent-Eligible Subject Matter Patents SCOTUS USPTO

USPTO Holds Forum on Subject Matter Eligibility -- Part II

Last Friday, the U.S. Patent and Trademark Office held a four-hour long forum to receive public feedback on the Myriad-Mayo Guidance, which was issued by the Office on March 4. According to the Office's Guidance webpage, the...more

5/15/2014 - Forum Myriad Patent Examinations Patent-Eligible Subject Matter Patents Public Comment SCOTUS USPTO

USPTO Guidance Takes an Expansive View of Patent-Ineligible Subject Matter

On March 4, in a memorandum issued to the Patent Examining Corps by Deputy Commissioner for Patent Examination Policy Andrew Hirshfeld, the U.S. Patent and Trademark Office (“USPTO”) implemented a new procedure for...more

5/12/2014 - Patent Litigation Patent-Eligible Subject Matter Patents USPTO

In re Roslin Institute (Fed. Cir. 2014) - Dolly the Sheep Not Patent Eligible Subject Matter

Earlier today, the Federal Circuit affirmed a determination by the Patent Trial and Appeal Board affirming the rejection of claims 155-159 and 164 of U.S. Application No. 09/225,233 as being directed to unpatentable subject...more

5/9/2014 - Genetic Materials Myriad Patent-Eligible Subject Matter Patents USPTO

Indiana Governor Signs Biosimilar Substitution Bill

On March 25, Indiana Governor Mike Pence signed legislation (Senate Bill 262) that will allow pharmacists in Indiana to substitute an interchangeable biosimilar product for a prescribed biological product if certain...more

4/11/2014 - Biosimilars FDA Healthcare Patents Pharmaceutical Pharmacies Prescription Drugs

House and Senate Bills Would Provide Incentive for Repurposing Old Biologics

Last month, Sen. Richard Blumenthal (D-CT) and Rep. Joaquin Castro (D-TX) introduced legislation in the Senate and House, respectively, that would extend the term of certain patents claiming a method of using a biological...more

4/10/2014 - Biologics Patent Reform Patents Pharmaceutical

107 Results
|
View per page
Page: of 5